Gb Sciences' First-in-Class Parkinson's Disease Therapy Successfully Completes Dose Response Study a

The Parkinson's disease market is expected to grow to $12.8 billion by 2028. Brain Parkinsons Study LAS VEGAS, July 11, 2023 (Newswire.com) - Gb Sciences, Inc. (OTCQB:GBLX), a leading cannabis- and plant...

Related Keywords

Canada ,Canadian ,Robert Sutherland ,Neurocage Systems Ltd ,Board Of Governors Research ,Michigan State University ,Gb Sciences ,University Of Lethbridge ,Department Of Neuroscience ,Contract Research Organizations ,Gbs Global Biopharma Inc ,Canadian Centre For Behavioral Neuroscience ,Gb Sciences Inc ,National Research Council Of Canada ,Exchange Commission ,Investigational New Drug Application ,Andrea Small Howard ,Chief Science Officer ,Governors Research Chair ,Canadian Centre ,Behavioral Neuroscience ,Cage Small ,Artificial Intelligence ,Neurocage Systems ,Gbs Global ,Gbs Global Biopharma ,Good Manufacturing ,National Research Council ,Cytokine Release Syndrome ,Michigan State ,Contract Research ,Elder Bruce Wolf Child ,Sacred Buffalo ,Post Secondary Learning ,Contact Information ,